In last years, Dr. Salas-Salvadó’ expertise and research lines focused on human clinical trials evaluating the effect of diets and dietary compounds on obesity, type 2 diabetes mellitus, metabolic syndrome and cardiovascular disease. Since 2005, he is one of the leaders of the PREDIMED study, a landmark trial evaluating the effect of the Mediterranean Diet on the primary prevention of cardiovascular diseases. He is the Director and Chair of the Steering Committee of the PREDIMED-PLUS study, an ongoing multi-centre, randomised, primary prevention trial on 6,900 overweight or obese participants (age 55-75 years) with metabolic syndrome. The project aims to determine the effects on cardiovascular disease events and mortality, adiposity, cardiovascular risk factors and quality of life, of an intensive weight loss intervention based on a traditional hypocaloric Mediterranean Diet, physical activity promotion and behavioral support compared to a less intensive program using Mediterranean Diet (without energy restriction nor physical activity). Recruitment started in September 2013 and ended in November 2016. The final results will be available in 2024. With all these projects and collaborations, his group has also developed skills in precision medicine using different OMIC´s methodologies, especially metabolomics and metagenomics, which are now implementing in epidemiologic and clinical studies.